Tempus reported preliminary Q4 revenue up ~83% year‑over‑year and full‑year 2025 revenue of about $1.27 billion, driven by diagnostics and data licensing deals. Guardant Health said preliminary Q4 revenue rose ~39% to $280 million, powered by oncology and Shield screening test volume gains. Both firms pointed to large contract wins and expanding clinical test volumes — including population screening and oncology workflows — as core growth engines. The companies emphasized scaling data and insights businesses alongside testing services; forthcoming JP Morgan presentations are set to outline commercialization plans and partner agreements.